Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
Polaris Group Identifier:
First received: September 11, 2013
Last updated: April 13, 2016
Last verified: April 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2016
  Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)